Health
GLP-1 Drugs May Slightly Raise Bone and Gout Risks
Health Points
- Osteoporosis affected 4.1% of GLP-1 users versus 3.2% of nonusers, a 29% relative rise.
- Gout hit 7.4% of users compared to 6.6% of nonusers, up 12% relatively.
- Prioritize calcium, vitamin D, balanced nutrition, and exercise to safeguard bone and joint health.
New research links GLP-1 drugs like Ozempic and Wegovy to slightly higher osteoporosis and gout risks in adults with type 2 diabetes and obesity.
Over five years, risks increased modestly, but experts stress monitoring and lifestyle tweaks can counter them effectively.
Researchers analyzed records from over 146,000 matched patients, noting small absolute differences.
Rapid weight loss and reduced nutrient intake may contribute by impacting bone density and uric acid levels.
“These medications should be a jump start toward a healthy lifestyle with diet and exercise, not a substitute,” says lead author John Gabriel Horneff III, MD.
“One theory is that the curbed appetite simply decreases the intake of important nutrients and vitamins for bone health, such as calcium and vitamin D,” says Dr. Horneff.
Observational data limits causation proof, missing details like diet or activity levels.
This reinforces benefits of GLP-1s alongside heart and metabolic gains when paired with proactive wellness.
Talk to your doctor about bone scans, supplements, and strength training to stay strong at any age.